Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Study of Venetoclax and Irinotecan in Relapsed/Refractory Small Cell Lung Cancer
Conditions
Interventions
Venetoclax 50 MG
Venetoclax 100 MG
+5 more
Start Date
June 30, 2021
Primary Completion Date
May 30, 2028
Completion Date
June 30, 2028
Last Updated
March 3, 2021
NCT06681220
NCT04421352
Lead Sponsor
Virginia Commonwealth University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions